Clinical Trial:

PHASE I/IIA STUDY OF THE ORAL 5-AZACITIDINE IN COMBINATION WITH THE HISTONE DEACETYLASE INHIBITOR ROMIDEPSIN FOR THE TREATMENT OF PATIENTS WITH RELAPSED AND REFRACTORY LYMPHOID MALIGNANCIES

This is an open label, phase I/IIa, 3 x 3 dose-escalation study of the combination of oral 5-azacytidine and the histone deacetylase inhibitor romidepsin for the treatment of patients with relapsed and refractory lymphoma.

 

Patients will take oral 5-azacytidine on Days 1 – 14 (+/- day 21) and romidepsin intravenously weekly on Days 8, 15 (+/- 22) on a 28-day treatment cycle.  In all cycles romidepsin will be administered first over 4 hours.